Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Status:
RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.